Regulation and Effects of FGF23 in Chronic Kidney Disease

Annual Review of Physiology

Volumn 82, Issue , 2020, Pages 365-390

  Musgrove, John ^a   Wolf, Myles ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

cardiovascular disease; chronic kidney disease; fibroblast growth factor 23; inflammation; iron; Klotho

Indexed keywords

BUROSUMAB; CALCIUM; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; NICOTINAMIDE; PHOSPHATE; TENAPANOR; FIBROBLAST GROWTH FACTOR;

ACUTE KIDNEY FAILURE; ANEMIA; ARTERY CALCIFICATION; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPOPHOSPHATEMIC RICKETS; INFECTION; KIDNEY TRANSPLANTATION; MORTALITY; NONHUMAN; PHOSPHATE METABOLISM; PRIORITY JOURNAL; REVIEW; ANIMAL; GENETICS;

ANIMALS; FIBROBLAST GROWTH FACTORS; HUMANS; RENAL INSUFFICIENCY, CHRONIC;

EID: 85079251163     PISSN: 00664278     EISSN: 15451585     Source Type: Book Series    
DOI: 10.1146/annurev-physiol-021119-034650     Document Type: Review

References (159)

1. Wolf M. 2015. Mineral (mal)adaptation to kidney disease-Young Investigator Award Address: American Society of Nephrology KidneyWeek 2014. Clin. J. Am. Soc. Nephrol. 10:1875-85
2. White KE, Evans WE, O'Riordan JLH, Speer MC, Econs MJ, et al. 2000. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 26:345-48
3. Brown EM, Pollak M, Seidman CE, Seidman JG, Chou YH, et al. 1995. Calcium-ion-sensing cell-surface receptors.N. Engl. J. Med. 333:234-40
4. Dusso AS, Brown AJ, Slatopolsky E. 2005. Vitamin D. Am. J. Physiol. Ren. Physiol. 289:F8-28
5. Moe SM. 2016. Calcium homeostasis in health and in kidney disease. Compr. Physiol. 6:1781-800
6. Bergwitz C, Juppner H. 2010. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu. Rev. Med. 61:91-104
7. Slatopolsky E, Robson AM, Elkan I, Bricker NS. 1968. Control of phosphate excretion in uremic man. J. Clin. Investig. 47:1865-74
8. Portale AA, Booth BE, Halloran BP, Morris RC Jr. 1984. Effect of dietary phosphorus on circulating concentrations of 1, 25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J. Clin. Investig. 73:1580-89
9. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, et al. 2001. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. PNAS 98:6500-5
10. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, et al. 2003. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.N. Engl. J. Med. 348:1656-63
11. Hu MC, Shiizaki K, Kuro-o M, Moe OW. 2013. Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu. Rev. Physiol. 75:503-33
12. Chen G, Liu Y, Goetz R, Fu L, Jayaraman S, et al. 2018. α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling. Nature 553:461-66
13. Wolf M, White KE. 2014. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr. Opin. Nephrol. Hypertens 23:411-19
14. Benet-Pagès A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom TM. 2004. FGF23 is processed by proprotein convertases but not by PHEX. Bone 35:455-62
15. Benet-Pagès A, Orlik P, Strom TM, Lorenz-Depiereux B. 2005. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum. Mol. Genet. 14:385-90
16. Tagliabracci VS, Engel JL, Wiley SE, Xiao J, Gonzalez DJ, et al. 2014. Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. PNAS 111:5520-25
17. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, et al. 2004. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Investig. 113:561-68
18. Gattineni J, Bates C, Twombley K, Dwarakanath V, Robinson ML, et al. 2009. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am. J. Physiol. Ren. Physiol. 297:F282-91
19. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, et al. 2004. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 19:429-35
20. Ferrari SL, Bonjour JP, Rizzoli R. 2005. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J. Clin. Endocrinol. Metab. 90:1519-24
21. Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, et al. 2005. Circulating FGF-23 is regulated by 1α, 25-dihydroxyvitamin D3 and phosphorus in vivo. J. Biol. Chem. 280:2543-49
22. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, et al. 2006. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J. Am. Soc. Nephrol. 17:1305-15
23. Mirams M, Robinson BG, Mason RS, Nelson AE. 2004. Bone as a source of FGF23: regulation by phosphate? Bone 35:1192-99
24. Bon N, Beck-Cormier S, Beck L. 2019. Interplay between FGF23, phosphate, and molecules involved in phosphate sensing. Curr. Mol. Biol. Rep. 5:1-7
25. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. 2010. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am. J. Physiol. Ren. Physiol. 299:F882-89
26. David V, Dai B, Martin A, Huang J, Han X, Quarles LD. 2013. Calcium regulates FGF-23 expression in bone. Endocrinology 154:4469-82
27. Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, et al. 2005. Vitamin D receptorindependent FGF23 actions in regulating phosphate and vitamin D metabolism. Am. J. Physiol. Ren. Physiol. 289:F1088-95
28. Gupta A, Winer K, Econs MJ, Marx SJ, Collins MT. 2004. FGF-23 is elevated by chronic hyperphosphatemia. J. Clin. Endocrinol. Metab. 89:4489-92
29. Eisenberg E. 1965. Effects of serum calcium level and parathyroid extracts on phosphate and calcium excretion in hypoparathyroid patients. J. Clin. Investig. 44:942-46
30. Collins MT, Lindsay JR, Jain A, Kelly MH, Cutler CM, et al. 2005. Fibroblast growth factor-23 is regulated by 1α, 25-dihydroxyvitamin D. J. Bone Miner. Res. 20:1944-50
31. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, et al. 2002. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J. Clin. Endocrinol. Metab. 87:4957-60
32. Edmonston D, Wolf M. 2019. FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. Nat. Rev. Nephrol. https://doi.org/10.1038/s41581-019-0189-5
33. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, et al. 2005. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J. Am. Soc. Nephrol. 16:2205-15
34. Portale AA, Wolf M, Jüppner H, Messinger S, Kumar J, et al. 2014. Disordered FGF23 and mineral metabolism in children with CKD. Clin. J. Am. Soc. Nephrol. 9:344-53
35. Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, et al. 2010. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int. 78:975-80
36. Wolf M, Koch TA, Bregman DB. 2013. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J. Bone Miner. Res. 28:1793-803
37. Wolf M, Chertow GM, Macdougall IC, Kaper R, Krop J, Strauss W. 2018. Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight 3:124486
38. Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, et al. 2004. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am. J. Kidney Dis. 44:250-56
39. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, et al. 1997. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390:45-51
40. Jüppner H, Wolf M.2012. αKlotho: FGF23 coreceptor and FGF23-regulating hormone. J. Clin. Investig. 122:4336-39
41. Smith RC, O'Bryan LM, Farrow EG, Summers LJ, Clinkenbeard EL, et al. 2012. Circulating αKlotho influences phosphate handling by controlling FGF23 production. J. Clin. Investig. 122:4710-15
42. Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, et al. 2011. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 79:1370-78
43. Smith ER, Cai MM, McMahon LP, Holt SG. 2012. Biological variability of plasma intact andC-terminal FGF23 measurements. J. Clin. Endocrinol. Metab. 97:3357-65
44. Shimada T, Urakawa I, Isakova T, Yamazaki Y, Epstein M, et al. 2010. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J. Clin. Endocrinol. Metab. 95:578-85
45. Stubbs JR, He N, Idiculla A, Gillihan R, Liu S, et al. 2012. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J. Bone Miner. Res. 27:38-46
46. Neuburg S, Dussold C, Gerber C, Wang X, Francis C, et al. 2018. Genetic background influences cardiac phenotype in murine chronic kidney disease. Nephrol. Dial. Transplant. 33:1129-37
47. Deleted in proof
48. Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, et al. 2011. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knockin mice. PNAS 108:E1146-55
49. David V, Martin A, Isakova T, Spaulding C, Qi L, et al. 2016. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 89:135-46
50. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. 2004. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. 15:2208-18
51. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, et al. 2005. Serum phosphate levels and mortality risk among people with chronic kidney disease. J. Am. Soc. Nephrol. 16:520-28
52. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G. 2005. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112:2627-33
53. Li X, Yang H-Y, Giachelli CM. 2006. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ. Res. 98:905-12
54. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, et al. 2008. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.N. Engl. J. Med. 359:584-92
55. Isakova T, Xie H, Yang W, et al. 2011. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305:2432-39
56. Isakova T, Cai X, Lee J, Xie D, Wang X, et al. 2018. Longitudinal FGF23 trajectories and mortality in patients with CKD. J. Am. Soc. Nephrol. 29:579-90
57. Wolf M, Molnar MZ, Amaral AP, Czira ME, Rudas A, et al. 2011. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J. Am. Soc. Nephrol. 22:956-66
58. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, et al. 2010. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann. Intern. Med. 152:640-48
59. Ix JH, Katz R, Kestenbaum BR, de Boer IH, Chonchol M, et al. 2012. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J. Am. Coll. Cardiol. 60:200-7
60. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, et al. 2011. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J. Am. Soc. Nephrol. 22:1913-22
61. Marthi A, Donovan K, Haynes R, Wheeler DC, Baigent C, et al. 2018. Fibroblast growth factor-23 and risks of cardiovascular and noncardiovascular diseases: a meta-analysis. J. Am. Soc.Nephrol. 29:2015-27
62. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. 2004. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J.Med. 351:1296-305
63. Seiler S, Reichart B, Roth D, Seibert E, Fliser D, Heine GH. 2010. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol. Dial. Transplant. 25:3983-89
64. Wright CB, Dong C, Stark M, Silverberg S, Rundek T, et al. 2014. Plasma FGF23 and the risk of stroke: the Northern Manhattan Study (NOMAS). Neurology 82:1700-6
65. Panwar B, Jenny NS, Howard VJ, Wadley VG, Muntner P, et al. 2015. Fibroblast growth factor 23 and risk of incident stroke in community-living adults. Stroke 46:322-28
66. Mehta R, Cai X, Lee J, Scialla JJ, Bansal N, et al. 2016. Association of fibroblast growth factor 23 with atrial fibrillation in chronic kidney disease, from the Chronic Renal Insufficiency Cohort Study. JAMA Cardiol. 1:548-56
67. Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, et al. 2014. Fibroblast growth factor-23 and cardiovascular events in CKD. J. Am. Soc. Nephrol. 25:349-60
68. Taylor EN, Rimm EB, Stampfer MJ, Curhan GC. 2011. Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am. Heart J. 161:956-62
69. Kestenbaum B, Sachs MC, Hoofnagle AN, Siscovick DS, Ix JH, et al. 2014. Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis. Circ. Heart Fail. 7:409-17
70. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, et al. 2011. FGF23 induces left ventricular hypertrophy. J. Clin. Investig. 121:4393-408
71. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, et al. 2009. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119:2545-52
72. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE. 2009. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 207:546-51
73. Touchberry CD, Green TM, Tchikrizov V, Mannix JE, Mao TF, et al. 2013. FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am. J. Physiol. Endocrinol. Metab. 304:E863-73
74. Kao YH, Chen YC, Lin YK, Shiu RJ, Chao TF, et al. 2014. FGF-23 dysregulates calcium homeostasis and electrophysiological properties in HL-1 atrial cells. Eur. J. Clin. Investig. 44:795-801
75. Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, et al. 2015. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab. 22:1020-32
76. Leifheit-Nestler M, Haffner D. 2018. Paracrine effects of FGF23 on the heart. Front. Endocrinol. 9:278
77. Hao H, Li X, Li Q, Lin H, Chen Z, et al. 2016. FGF23 promotes myocardial fibrosis in mice through activation of β-catenin. Oncotarget 7:64649-64
78. Andrukhova O, Slavic S, Odorfer KI, Erben RG. 2015. Experimental myocardial infarction upregulates circulating fibroblast growth factor-23. J. Bone Miner. Res. 30:1831-39
79. Richter M, Lautze HJ, Walther T, Braun T, Kostin S, Kubin T. 2015. The failing heart is a major source of circulating FGF23 via oncostatin M receptor activation. J. Heart Lung Transplant. 34:1211-14
80. Zhang Q, Doucet M, Tomlinson RE, Han X, Quarles LD, et al. 2016. The hypoxia-inducible factor-1α activates ectopic production of fibroblast growth factor 23 in tumor-induced osteomalacia. Bone Res. 4:16011
81. Xie J, Cha SK, An SW, Kuro OM, Birnbaumer L, Huang CL. 2012. Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart. Nat. Commun. 3:1238
82. Hu MC, Shi M, Cho HJ, Adams-Huet B, Paek J, et al. 2015. Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. J. Am. Soc. Nephrol. 26:1290-302
83. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, et al. 2000. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. 342:1478-83
84. Roos M, Lutz J, Salmhofer H, Luppa P, Knauss A, et al. 2008. Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function. Clin. Endocrinol. 68:660-65
85. Coen G, De Paolis P, Ballanti P, Pierantozzi A, Pisano S, et al. 2011. Peripheral artery calcifications evaluated by histology correlate to those detected by CT: relationships with fetuin-A and FGF-23. J. Nephrol. 24:313-21
86. Inaba M, Okuno S, Imanishi Y, Yamada S, Shioi A, et al. 2006. Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos. Int. 17:1506-13
87. Nasrallah MM, El-Shehaby AR, Salem MM, Osman NA, El Sheikh E, Sharaf El Din UA. 2010. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol. Dial. Transplant. 25:2679-85
88. Scialla JJ, Lau WL, Reilly MP, Isakova T, Yang H-Y, et al. 2013. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int. 83:1159-68
89. Jimbo R, Kawakami-Mori F, Mu S, Hirohama D, Majtan B, et al. 2014. Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. Kidney Int. 85:1103-11
90. Lim K, Lu T-S, Molostvov G, Lee C, Lam FT, et al. 2012. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 125:2243-55
91. Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, et al. 2004. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem. Biophys. Res. Commun. 314:409-14
92. Faul C, Wolf M. 2015. Hunt for the culprit of cardiovascular injury in kidney disease. Cardiovasc. Res. 108:209-11
93. Mencke R, Harms G, Mirkovic K, Struik J, Van Ark J, et al. 2015. Membrane-bound Klotho is not expressed endogenously in healthy or uraemic human vascular tissue. Cardiovasc. Res. 108:220-31
94. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, et al. 2007. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J. Am. Soc. Nephrol. 18:2600-8
95. Scialla JJ, Astor BC, Isakova T, Xie H, Appel LJ, Wolf M. 2013. Mineral metabolites and CKD progression in African Americans. J. Am. Soc. Nephrol. 24:125-35
96. Rebholz CM, Grams ME, Coresh J, Selvin E, Inker LA, et al. 2015. Serum fibroblast growth factor-23 is associated with incident kidney disease. J. Am. Soc. Nephrol. 26:192-200
97. Isakova T, Craven TE, Lee J, Scialla JJ, Xie H, et al. 2015. Fibroblast growth factor 23 and incident CKD in type 2 diabetes.Clin. J. Am. Soc.Nephrol. 10:29-38
98. Wolf M. 2015. The biomarker niche for fibroblast growth factor 23 testing in CKD. J. Am. Soc. Nephrol. 26:7-9
99. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. 2002. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch. Intern. Med. 162:1401-8
100. Weiss G, Goodnough LT. 2005. Anemia of chronic disease.N. Engl. J. Med. 352:1011-23
101. Mehta R, Cai X, Hodakowski A, Lee J, Leonard M, et al. 2017. Fibroblast growth factor 23 and anemia in the Chronic Renal Insufficiency Cohort Study. Clin. J. Am. Soc. Nephrol. 12:1795-803
102. Daryadel A, Bettoni C, Haider T, Imenez Silva PH, Schnitzbauer U, et al. 2018. Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men. Pflügers Arch. 470:1569-82
103. Coe LM, Madathil SV, Casu C, Lanske B, Rivella S, Sitara D. 2014. FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. J. Biol. Chem. 289:9795-810
104. Mendoza JM, Isakova T, Ricardo AC, Xie H, Navaneethan SD, et al. 2012. Fibroblast growth factor 23 and inflammation in CKD.Clin. J. Am. Soc. Nephrol. 7:1155-62
105. Singh S, Grabner A, Yanucil C, Schramm K, Czaya B, et al. 2016. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int. 90:985-96
106. Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, et al. 2008. Aspects of immune dysfunction in end-stage renal disease. Clin. J. Am. Soc. Nephrol. 3:1526-33
107. Chonchol M, Greene T, Zhang Y, Hoofnagle AN, Cheung AK. 2016. Low vitaminDand high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO Study. J. Am. Soc. Nephrol. 27:227-37
108. Rossaint J, Oehmichen J, Van Aken H, Reuter S, Pavenstädt HJ, et al. 2016. FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J. Clin. Investig. 126:962-74
109. Haddad LE, Khzam LB, Hajjar F, Merhi Y, Sirois MG. 2011. Characterization of FGF receptor expression in human neutrophils and their contribution to chemotaxis. Am. J. Physiol. Cell Physiol. 301:C1036-45
110. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, et al. 2006. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311:1770-73
111. Bacchetta J, Sea JL, Chun RF, Lisse TS, Wesseling-Perry K, et al. 2013. Fibroblast growth factor 23 inhibits extrarenal synthesis of 1, 25-dihydroxyvitamin D in human monocytes. J. Bone Miner. Res. 28:46-55
112. Gruson D, Ferracin B, Ahn SA, Rousseau MF. 2015. Comparison of fibroblast growth factor 23, soluble ST2 and Galectin-3 for prognostication of cardiovascular death in heart failure patients. Int. J. Cardiol. 189:185-87
113. Poelzl G, Trenkler C, Kliebhan J, Wuertinger P, Seger C, et al. 2014. FGF23 is associated with disease severity and prognosis in chronic heart failure. Eur. J. Clin. Investig. 44:1150-58
114. Udell JA, Morrow DA, Jarolim P, Sloan S, Hoffman EB, et al. 2014. Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. J. Am. Coll. Cardiol. 63:2421-28
115. Wohlfahrt P, Melenovsky V, Kotrc M, Benes J, Jabor A, et al. 2015. Association of fibroblast growth factor-23 levels and angiotensin-converting enzyme inhibition in chronic systolic heart failure. JACC Heart Fail. 3:829-39
116. Murugan R, Kellum JA. 2011. Acute kidney injury: What's the prognosis? Nat. Rev. Nephrol. 7:209-17
117. Christov M, Waikar SS, Pereira RC, Havasi A, Leaf DE, et al. 2013. Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int. 84:776-85
118. Leaf DE, Christov M, Jüppner H, Siew E, Ikizler TA, et al. 2016. Fibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgery. Kidney Int. 89:939-48
119. Leaf DE, Jacob KA, Srivastava A, Chen ME, Christov M, et al. 2017. Fibroblast growth factor 23 levels associate with AKI and death in critical illness. J. Am. Soc. Nephrol. 28:1877-85
120. Carpenter TO, Whyte MP, Imel EA, Boot AM, Högler W, et al. 2018. Burosumab therapy in children with X-linked hypophosphatemia.N. Engl. J. Med. 378:1987-98
121. Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, et al. 2012. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J. Clin. Investig. 122:2543-53
122. Isakova T, Gutiérrez OM, Smith K, Epstein M, Keating LK, et al. 2010. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol. Dial. Transplant. 26:584-91
123. Sigrist M, Tang M, Beaulieu M, Levin A, Espino-Hernandez G, et al. 2012. Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial. Nephrol. Dial. Transplant. 28:161-69
124. Isakova T, Barchi-Chung A, Enfield G, Smith K, Vargas G, et al. 2013. Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. Clin. J. Am. Soc. Nephrol. 8:1009-18
125. Nishida Y, Taketani Y, Yamanaka-Okumura H, Imamura F, Taniguchi A, et al. 2006. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int. 70:2141-47
126. Kalantar-Zadeh K, Gutekunst L, Mehrotra R, Kovesdy CP, Bross R, et al. 2010. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 5:519-30
127. Isakova T, Ix JH, Sprague SM, Raphael KL, Fried L, et al. 2015. Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD. J. Am. Soc. Nephrol. 26:2328-39
128. Moe SM, Chen NX, Seifert MF, Sinders RM, Duan D, et al. 2009. A rat model of chronic kidney diseasemineral bone disorder. Kidney Int. 75:176-84
129. Moe SM, Zidehsarai MP, Chambers MA, Jackman LA, Radcliffe JS, et al. 2011. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 6:257-64
130. Krieger NS, Culbertson CD, Kyker-Snowman K, Bushinsky DA. 2012. Metabolic acidosis increases fibroblast growth factor 23 in neonatal mouse bone. Am. J. Physiol. Ren. Physiol. 303:F431-36
131. Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, et al. 2010. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin. J. Am. Soc. Nephrol. 5:286-91
132. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, et al. 2012. Effects of phosphate binders in moderate CKD. J. Am. Soc. Nephrol. 23:1407-15
133. Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A, Martinez-Calero A, Navas V, et al. 2011. Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients. Nephrol. Dial. Transplant. 26:2567-71
134. Ix JH, Isakova T, Larive B, Raphael KL, Raj DS, et al. 2019. Effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor-23 in CKD: the COMBINE Trial. J. Am. Soc. Nephrol. 30:1096-1108
135. Chue CD, Townend JN, Moody WE, Zehnder D, Wall NA, et al. 2013. Cardiovascular effects of sevelamer in stage 3 CKD. J. Am. Soc. Nephrol. 24:842-52
136. Block GA, Fishbane S, Rodriguez M, Smits G, Shemesh S, et al. 2015. A 12-week, double-blind, placebocontrolled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5. Am. J. Kidney Dis. 65:728-36
137. Shima H, Miya K, Okada K, Minakuchi J, Kawashima S. 2018. Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients. BMC Res. Notes 11:363
138. Umanath K, Jalal DI, Greco BA, Umeukeje EM, Reisin E, et al. 2015. Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD. J. Am. Soc. Nephrol. 26:2578-87
139. Schiavi SC, Tang W, Bracken C, O'Brien SP, Song W, et al. 2012. Npt2b deletion attenuates hyperphosphatemia associated with CKD. J. Am. Soc. Nephrol. 23:1691-700
140. Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW. 2008. A randomized, double-blind, placebocontrolled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 3:1131-38
141. Rao M, Steffes M, Bostom A, Ix JH. 2014. Effect of niacin on FGF23 concentration in chronic kidney disease.Am. J. Nephrol. 39:484-90
142. Block GA, Rosenbaum DP, Yan A, Greasley PJ, Chertow GM, Wolf M. 2018. The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia. Nephrol. Dial. Transplant. 34:339-46
143. Saito A, Nikolaidis NM, Amlal H, Uehara Y, Gardner JC, et al. 2015. Modeling pulmonary alveolar microlithiasis by epithelial deletion of the Npt2b sodium phosphate cotransporter reveals putative biomarkers and strategies for treatment. Sci. Transl. Med. 7:313ra181
144. Spencer AG, Labonte ED, Rosenbaum DP, Plato CF, Carreras CW, et al. 2014. Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans. Sci. Transl.Med. 6:227ra36
145. Finch JL, Tokumoto M, Nakamura H, Yao W, Shahnazari M, et al. 2010. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am. J. Physiol. Ren. Physiol. 298:F1315-22
146. Charytan C, Coburn JW, Chonchol M, Herman J, Lien YH, et al. 2005. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am. J. Kidney Dis. 46:58-67
147. Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD. 2010. Effects of cinacalcet and concurrent lowdose vitamin D on FGF23 levels in ESRD. Clin. J. Am. Soc. Nephrol. 5:110-16
148. Koizumi M, Komaba H, Nakanishi S, Fujimori A, Fukagawa M. 2012. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol. Dial. Transplant. 27:784-90
149. Sprague SM, Wetmore JB, Gurevich K, Da Roza G, Buerkert J, et al. 2015. Effect of cinacalcet and vitamin D analogs on fibroblast growth factor-23 during the treatment of secondary hyperparathyroidism. Clin. J. Am. Soc. Nephrol. 10:1021-30
150. Wolf M, Block GA, Chertow GM, Fouqueray B, Tomlin H, et al. 2019. Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis. Clin. Kidney J. https://doi.org/10.1093/ckj/sfz034
151. Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, et al. 2015. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation 132:27-39
152. Middleton JP, Wolf M. 2017. Second chances to improve ESRD outcomes with a second-generation calcimimetic. JAMA 317:139-41
153. Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, et al. 2012. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.N. Engl. J. Med. 367:2482-94
154. Wöhrle S, Henninger C, Bonny O, Thuery A, Beluch N, et al. 2013. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J. Bone Miner. Res. 28:899-911
155. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, et al. 2005. Suppression of aging in mice by the hormone Klotho. Science 309:1829-33
156. Hu MC, Shi M, Gillings N, Flores B, Takahashi M, et al. 2017. Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy. Kidney Int. 91:1104-14
157. Grabner A, Faul C. 2016. The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy. Curr. Opin. Nephrol. Hypertens 25:314-24
158. Bhan I, Shah A, Holmes J, Isakova T, Gutierrez O, et al. 2006. Post-transplant hypophosphatemia: Tertiary 'hyper-phosphatoninism'? Kidney Int. 70:1486-94
159. Wolf M, Weir MR, Kopyt N, Mannon RB, Von Visger J, et al. 2016. A prospective cohort study of mineral metabolism after kidney transplantation. Transplantation 100:184-93